IL15: Interleukin-15
Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on IL15, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Ordesekimab | Phase 2 | Amgen | Antibody | InhibitorInterleukin-15 inhibitor | 0 |
- Hypothyroidism0.39
- Smoking initiation0.36
- Post term pregnancy0.32
- Atopic eczema0.31
- Hypertrophic cardiomyopathy0.30
- Placenta praevia0.29
- Alcohol drinking0.28
- Response to radiation0.28
- Urolithiasis0.27
- Abnormal nasolacrimal system morphology0.27
- Brain cancer0.27
- Parasitic infectious disease0.20
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712954, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P40933, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets